Kymera Therapeutics (NASDAQ:KYMR) Hits New 12-Month High at $45.55

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price reached a new 52-week high on Monday . The company traded as high as $45.55 and last traded at $45.00, with a volume of 756375 shares changing hands. The stock had previously closed at $42.30.

Wall Street Analysts Forecast Growth

KYMR has been the subject of a number of recent analyst reports. Oppenheimer reissued an “outperform” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a report on Wednesday, July 10th. B. Riley lifted their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of “Hold” and an average price target of $42.09.

Kymera Therapeutics Stock Up 6.4 %

The business’s 50 day moving average price is $33.94 and its 200-day moving average price is $34.89. The company has a market cap of $2.76 billion, a PE ratio of -17.67 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The firm had revenue of $10.30 million during the quarter, compared to the consensus estimate of $14.24 million. During the same quarter in the prior year, the business posted ($0.70) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 8.4% on a year-over-year basis. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the completion of the transaction, the director now directly owns 803,792 shares in the company, valued at $28,494,426.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total transaction of $593,433.00. Following the transaction, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Joanna Horobin sold 8,500 shares of Kymera Therapeutics stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $32.99, for a total value of $280,415.00. The disclosure for this sale can be found here. Insiders have sold 479,200 shares of company stock worth $18,219,660 over the last ninety days. 15.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KYMR. Price T Rowe Associates Inc. MD lifted its stake in shares of Kymera Therapeutics by 5.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company’s stock worth $135,848,000 after buying an additional 278,287 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Kymera Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock worth $101,778,000 after purchasing an additional 72,351 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Kymera Therapeutics in the 4th quarter valued at approximately $792,000. BVF Inc. IL increased its position in Kymera Therapeutics by 8.9% in the 4th quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock worth $131,419,000 after buying an additional 422,797 shares during the period. Finally, Jennison Associates LLC acquired a new position in shares of Kymera Therapeutics during the first quarter worth approximately $17,122,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.